White House science/tech panel outlines path for doubling new medicines
This article was originally published in Scrip
To improve drug discovery and development in the US, the federal government should strongly support funding for basic biomedical research, catalyze the creation of a broad-based partnership to speed therapies to market and expand the use of the FDA's existing authorities for accelerated approval, a panel of advisers to President Barack Obama said in a new report.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.